Vimarsana
Biggest News Aggregation in the World

Nat Commun News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nat Commun. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nat Commun Today - Breaking & Trending Today

Urolithin A supplementation for longevity and healthy aging - Vimarsana News

Urolithin A supplementation for longevity and healthy aging

Urolithin A is a metabolite with profound health benefits and potential longevity effects.

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting - Vimarsana News

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

NEW YORK, May 22, 2024 -- MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant...

N-fertilizers have changed how we farm, what we farm and what we eat - Vimarsana News

N-fertilizers have changed how we farm, what we farm and what we eat

While the links and mechanisms are not totally apparent, the introduction of synthetic fertilizers broke most of the links between the land, the animals and the people. This separation has many results and impacts on what we eat.

How nitrogen fertilizers changed the food system. Part 1. - Vimarsana News

How nitrogen fertilizers changed the food system. Part 1.

Nitrogen (N) is on the one hand an essential nutrient for all life forms and the building block for proteins, and on the other hand a pollutant causing many negative environmental and human health impacts.

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates - Vimarsana News

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Longer follow up and subset analyses from the pivotal FELIX Phase 2 data to be presented in oral presentations at ASCO and EHATwo patients enrolled in Phase 1 Systemic Lupus Erythematosus trial;...